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Purpose: To present the safety and efﬁcacy of intravitreal implants releasing 0.2 mg/day ﬂuocinolone acetonide
(FAc) in patients with chronic versus nonchronic diabetic macular edema (DME). To assess ocular characteristics,
anatomic changes, and re-treatment and ancillary therapies that may explain the differential treatment effect seen
with intravitreal implants releasing FAc 0.2 mg/day in patients with chronic and nonchronic DME. An overall beneﬁt-
to-risk assessment for the FAc 0.2-mg/day and FAc 0.5-mg/day doses has been reported previously.
Design: Preplanned subgroup analysis of chronic (duration of diagnosis, 3 years) and nonchronic (duration
of diagnosis, <3 years) DME in patients from 2 randomized, sham injection-controlled, double-masked, multi-
center clinical trials.
Participants: Patients with persistent DME despite 1 or more macular laser treatment were randomized 1:2:2
to sham injection (n ¼ 185), FAc 0.2 mg/day (n ¼ 375), or FAc 0.5 mg/day (n ¼ 393).
Methods: Patients received study drug or sham injection and after 6 weeks were eligible for rescue laser.
Based on re-treatment criteria, additional masked study drug could be given after 1 year.
Main Outcome Measures: Percentage of patients with improvement of 15 letters or more from baseline.
Secondary outcomes included other parameters of visual function and foveal thickness.
Results: At month 36, the difference between FAc 0.2 mg/day and sham control in the percentage of patients
who gained 15 letters or more was signiﬁcantly greater in chronic DME patients (FAc 0.2 mg/day, 34.0% vs. sham,
13.4%; P<0.001), compared with patients with nonchronic DME (FAc 0.2 mg/day, 22.3% vs. sham, 27.8%; P ¼
0.275). The greater response in patients with chronic DME was not associated with baseline ocular character-
istics, changes in anatomic features, or differences in re-treatment or ancillary therapies. The ocular adverse event
proﬁle for FAc 0.2 mg/day was similar regardless of DME duration.
Conclusions: This is the ﬁrst published analysis correlating duration of diagnosis of DME with treatment
effect. In patients with chronic DME, FAc 0.2 mg/day provides substantial visual beneﬁt for up to 3 years and
would provide an option for patients who do not respond to other therapy. Ophthalmology 2014;121:1892-
1903 ª 2014 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
*Supplemental material is available at www.aaojournal.org.The prevalence of macular edema, the primary cause of
impaired vision in patients with diabetes, is increasing.1e3
Since 1985, the mainstay of treatment for diabetic macular
edema (DME) had been focal or grid photocoagulation.4
Surgical techniques, such as pars plana vitrectomy, with or
without internal limiting membrane removal, also have
shown efﬁcacy in some patients.5,6 Based on the discovery
that vascular endothelial growth factor (VEGF) plays a central
role in the increased vascular permeability associated with
DME,7 the ﬁrst pharmacotherapy, the anti-VEGF antibody
ranibizumab, was approved in 2012 for treatment of DME.81892  2014 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). Published by Elsevier IncThis approval was based on the results of 2 phase 3 clinical
trials (A Study of Ranibizumab Injection in Subjects with
Clinically Signiﬁcant Macular Edema with Center
Involvement Secondary to Diabetes Mellitus [RIDE/RISE]),
which compared 2 doses of ranibizumab to sham injection,
with rescue laser available 3 months after randomization.9
Before these trials, the Diabetic Retinopathy Clinical
Research Network undertook protocol I, which compared
ranibizumab plus prompt or deferred laser versus
triamcinolone plus prompt laser versus sham injections plus
prompt laser.10.
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to the sham control arm were crossed over to monthly in-
jection of ranibizumab 0.5 mg after the primary time point of
2 years. However, in both trials, after treatment with ranibi-
zumab for 1 year, the crossover group was unable to achieve
the margin of vision improvement achieved by patients who
were randomized initially to ranibizumab treatment arms.11
In the combined dataset, the proportion of patients gaining
15 letters or more 12 months after ﬁrst ranibizumab
injection was 32.4% for those initially randomized to 0.3
mg ranibizumab, 31.7% for those randomized to 0.5 mg
ranibizumab, and 7.3% for patients randomized to sham
treatment after crossover to 0.5 mg ranibizumab.
Furthermore, in the Diabetic Retinopathy Clinical Research
Network protocol I trial, patients received a median of 10
or 12 ranibizumab injections over 2 years in the prompt
laser and deferred laser groups, respectively. However,
more than 50% of ranibizumab-treated eyes did not achieve
a visual acuity improvement from baseline of 10 letters or
more at year 2.12 Similarly, in RIDE, after 3 years of monthly
injections, 43.2% and 37.0% of patients in the 0.3- and 0.5-
mg ranibizumab arms, respectively, achieved an improve-
ment of fewer than 10 letters of visual acuity.11 In RISE,
these percentages were 30.4% and 42.4%, respectively. In
recognition of the need for additional treatments for DME,
the Diabetic Retinopathy Clinical Research Network has
initiated a phase 2 clinical trial assessing the combination
of steroid and anti-VEGF for persistent DME.13
Two identically designed phase 3 clinical trials, the
Fluocinolone Acetonide for Diabetic Macular Edema
(FAME) studies, FAME A and FAME B, compared 2 doses
of a nonbioerodible intravitreal implant-releasing submi-
crogram doses of the corticosteroid ﬂuocinolone acetonide
(FAc) with sham injection over a 3-year period.14,15 All
patients were eligible for laser photocoagulation 6 weeks
after randomization. A preplanned subgroup analysis was
performed that assessed the primary outcome of 15 or more
Early Treatment Diabetic Retinopathy Study (ETDRS) let-
ters of improvement from baseline as a function of median
duration of diagnosis of DME at baseline. This revealed
enhanced beneﬁt in that patients with chronic DME (dura-
tion, 3 years) demonstrated a signiﬁcant treatment effect
as compared with patients with nonchronic DME (duration,
<3 years).15 This result was highly statistically signiﬁcant
and was reproduced in both phase 3 trials. On the basis of
these results, FAc 0.2 mg/day (ILUVIEN; Alpharetta, GA)
received marketing authorizations after a positive opinion
in the decentralized procedure involving the United
Kingdom, Germany, France, Spain, Austria, and Portugal,
with Italy in the process of completing administrative
steps. These data have also been submitted to the United
States Food and Drug Administration.
This study explored the possible contribution of baseline
features and treatments received during the trial to the dif-
ferential treatment effect and examined the relationship be-
tween anatomic changes and visual acuity outcomes.
Additionally, new analyses related to the calculation of
duration of DME are presented, which add to the under-
standing of these results, and outcomes are examined in the
context of insufﬁcient responses observed in other phase 3DME studies among patients with chronic DME. We hy-
pothesized that microenvironmental changes occurring in
chronic DME may need a treatment strategy that targets
multiple mediators. This report primarily focuses on com-
parisons between the approved dose of FAc 0.2 mg/day and
sham control injection among patients with chronic or
nonchronic DME. An overall beneﬁt-to-risk assessment for
the FAc 0.2-mg/day and FAc 0.5-mg/day doses has been
reported previously.15
Methods
The FAME A and B studies were performed under a single protocol
as 36-month, randomized, double-masked, sham injection-
controlled, parallel-group, multicenter studies.14 Both studies
adhered to the guidelines of the Declaration of Helsinki, and the
protocol and consent form were approved by each institution’s
governing institutional review board or ethics committee. The
studies were compliant with the rules and regulations under the
Health Insurance Portability and Accountability Act of 1996. Each
patient provided written informed consent. These studies are
registered at www.clinicaltrials.gov (no. NCT00344968).
Study Population
Selection criteria for the study have been described.14 The study
enrolled patients who had a time-domain optical coherence to-
mography foveal thickness of at least 250 mm despite at least 1 prior
focal or grid macular laser photocoagulation treatment and best-
corrected visual acuity (BCVA) in ETDRS letter score between
19 and 68 (Snellen equivalent range, 20/50e20/400). Enrollment
was stratiﬁed by baseline BCVA score (letter score, 49 and >49).
Patients with glaucoma, ocular hypertension, or intraocular pressure
(IOP) of more than 21 mmHg or those receiving IOP-lowering
medication were excluded. A total of 956 patients were random-
ized 2:2:1 to receive FAc 0.2-mg/day intravitreal implant, FAc 0.5-
mg/day intravitreal implant, or sham injection in 1 eye. After 6
weeks, all patients were eligible for laser photocoagulation. After 12
months, all patients were eligible for re-treatment with randomized
study drug or sham injection if they lost 5 letters or more of BCVA
or experienced an increase in retinal center point thickness (CPT) of
50 mm or more from their best reading in the previous 12 months.
Other therapies such as anti-VEGF and intravitreal triamcinolone
acetonide, now considered part of the standard of care, were not
allowed to be included in the protocol because at the time of the
trial, they were not approved for DME. Some patients were pre-
scribed these off-protocol therapies to control their disease; these
patients were not removed from statistical analyses.
Assessments
Over the 3-year treatment period, study visits were scheduled at
screening, baseline, 1 week, 6 weeks, and 3 months after treatment
initiation, and every 3 months thereafter. One masked investigator
carried out the assessment, and another masked investigator carried
out the injections. Best-corrected visual acuity was measured with
the ETDRS chart at 4 m or with an electronic visual acuity tester at
3 m. Anatomic assessments included measurement of CPT and
macular volume with optical coherence tomography (Stratus OCT;
Carl Zeiss Meditec; Dublin, CA) and measurement of area of
ﬂuorescein leakage and area of cystoid edema with ﬂuorescein
angiography. The severity of diabetic retinopathy was graded with
the ETDRS Retinopathy Eye Scale after masked assessment of
angiograms and fundus photographs by an independent reading
center.1893
Table 1. Demographics and Baseline Characteristics in Patients with Chronic and Nonchronic DME
Nonchronic DME (<3 Years) Chronic DME (‡ 3 Years)
Sham Control
n ¼ 72
0.2 mg/day FAc
n ¼ 165
Sham Control
n ¼ 112
0.2 mg/day FAc
n ¼ 209
Age, mean (SD), years 60.2 (9.7) 62.0 (9.9) 62.9 (9.4) 63.7 (8.9)
Male, n (%) 40 (55.6) 94 (57.0) 68 (60.7) 120 (57.4)
Race, n (%)
White 54 (75.0) 110 (66.7) 77 (68.8) 153 (73.2)
Black 2 (2.8) 8 (4.8) 9 (8.0) 14 (6.7)
Asian 15 (20.8) 43 (26.1) 25 (22.3) 42 (20.1)
Other 1 (1.4) 3 (1.8) 1 (0.9) 0
Type 2 diabetes, n (%) 68 (94.4) 154 (93.3) 101 (90.2) 186 (89.0)
Time since diagnosis of diabetes, mean (SD), years 14.0 (8.4) 15.4 (9.1) 17.9 (8.3) 18.3 (9.4)
Time since diagnosis of DME, mean (SD), years 1.7 (0.5) 1.6 (0.5) 5.4 (4.2) 5.1 (3.1)
HbA1c, mean (SD), % 8.1 (1.9) 7.8 (1.6) 7.7 (1.5) 7.8 (1.6)
Diabetes treatment, n (%)
None 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.5)
Diet only 0 (0.0) 3 (1.8) 0 (0.0) 0 (0.0)
Oral 33 (45.8) 80 (48.5) 46 (41.1) 88 (42.1)
Insulin + oral 18 (25.0) 40 (24.2) 29 (25.3) 66 (31.6)
Insulin 21 (29.2) 41 (24.8) 37 (33.0) 54 (25.8)
Phakic at baseline, n (%) 54 (75.0) 121 (73.3) 66 (58.9) 114 (54.5)
IOP, mean (SD), mm Hg 14.8 (3.5) 15.4 (3.0) 15.2 (2.8) 15.0 (2.9)
BCVA, mean (SD), letters 55.7 (11.48) 54.7 (11.69) 54.0 (11.5) 52.2 (13.36)
Center point thickness, mean (SD), mm 435.0 (149.1) 466.6 (152.9) 461.8 (153.5) 456.2 (165.9)
Fluorescein leakage, mean (SD), total disc area 9.49 (4.40) 9.13 (4.52) 8.41 (4.41) 7.94 (4.49)
Cysts, mean (SD), total disc area 0.86 (1.34) 1.29 (1.83) 1.81 (2.79) 1.39 (2.02)
ETDRS classiﬁcation, mean (SD) 6.0 (1.61) 5.7 (1.61) 5.8 (1.64) 5.7 (1.51)
Macular volume, mean (SD), mm3 9.7 (1.9) 9.9 (2.0) 9.4 (2.2) 9.5 (2.3)
Previous treatments, n (%)
Corticosteroids
Intravitreal 9 (12.5) 24 (14.5) 19 (17.00) 39 (18.7)
Subtenon 3 (4.2) 3 (1.8) 5 (4.5) 3 (1.4)
Periocular 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
None 60 (83.3) 132 (80.0) 85 (75.9) 161 (77.0)
Missing 0 (0.0) 6 (3.6) 3 (2.7) 3 (1.4)
Intravitreal anti-VEGF 4 (5.6) 7 (4.2) 6 (5.4) 19 (9.1)
Laser scars assessment*
Deﬁnite scarring, n (%) 51 (70.8) 128 (77.6) 99 (88.4) 169 (80.9)
Area of retinal scarring (including area
between scars), mean (SD), total disc area
4.4 (2.8) 3.9 (2.8) 4.8 (3.0) 4.5 (3.0)
BCVA ¼ best corrected visual acuity; DME ¼ diabetic macular edema; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; FAc ¼ ﬂuocinolone
acetonide; IOP ¼ intraocular pressure; SD ¼ standard deviation; VEGF ¼ vascular endothelial growth factor.
*From a special reading center assessment of ﬂuorescein angiograms obtained at baseline.
Ophthalmology Volume 121, Number 10, October 2014Statistical Analyses
The effect of duration of diagnosis of DME on visual outcomes
was a preplanned subgroup analysis (less than the median vs. the
median or more). The duration of diagnosis of DME at randomi-
zation for each patient was based on information recorded by the
investigator at screening and was calculated using the prespeciﬁed
algorithm: year of initial study treatment minus year of diagnosis,
with addition of a value of 1 to ensure that no patients had a value
of 0. Because the median duration of DME determined by this
method was 3 years, visual and anatomic outcomes after treatment
with FAc implants or sham control treatment were compared in
patients with a duration of DME of less than 3 years (nonchronic)
versus 3 years or more (chronic). An additional post hoc algorithm
was also used to examine robustness of the data and to calculate
more precisely the duration of DME at baseline, based on the
speciﬁc day, month, and year of diagnosis of DME. When the day1894of diagnosis was not available, the ﬁfteenth of the month was
imputed for the day, and when only the year was available, a date
of July 1 was imputed. This resulted in a median of 1.73 years.
Concordance between the 2 algorithms was examined using a
simple k coefﬁcient.16 The primary outcome measure was the
percentage of patients with 15-letter or more improvement from
baseline in BCVA, which was determined for populations result-
ing from both subgroup algorithms. Pairwise comparisons were
made using a Cochrane-Mantel-Haenszel chi-square test stratiﬁed
by baseline visual acuity. Secondary outcome measures included
mean changes from baseline in BCVA, CPT, retinal volume,
ﬂuorescein leakage, cysts, and change in severity of diabetic
retinopathy (preplanned measure was worsening of 3 steps or
more on the ETDRS scale). Comparisons between treatments were
made using an analysis of variance model with treatment and
baseline visual acuity strata as ﬁxed effects with interaction. A
Hochberg-Bonferroni correction was used to adjust for multiple
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Figure 1. Graphs showing the proportion of patients with a 15-letter or more improvement from baseline in best-corrected visual acuity by study and
duration of diabetic macular edema (DME; 3 years or <3 years). Visual outcomes through month 36 in patients with chronic or nonchronic DME at
baseline treated with ﬂuocinolone acetonide (FAc) 0.2 mg/day or sham injection in the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) A and
FAME B studies. The full analysis population included all randomized patients. The method of last observation carried forward was used for imputing values
for missing data. In patients with chronic DME, a signiﬁcantly higher proportion of patients treated with FAc gained 15 letters or more from baseline
compared with the sham control group in both FAME studies: (A) FAME A: FAc 0.2 mg/day, 31.8% versus sham control, 13.6% (P ¼ 0.010); and (B)
FAME B: FAc 0.2 mg/day, 36.4% versus sham control, 13.2% (P ¼ 0.004). In patients with nonchronic DME, the percentage of patients who gained 15
letters or more from baseline was similar between FAc-treated and sham control groups in both studies: (C) FAME A: FAc 0.2 mg/day, 24.1% versus sham
control, 28.6% (P ¼ 0.441); (D) FAME B: FAc 0.2 mg/day, 20.7% versus sham control, 27.0% (P ¼ 0.424).
Cunha-Vaz et al  Fluocinolone Acetonide Implant for Chronic DMEcomparisons against the sham control. Results are presented for
the intent-to-treat population, which included all randomized pa-
tients, with imputation of data for missing values by the last
observation carried forward method.
Results
Patient Disposition and Baseline Characteristics
Of 956 patients randomized in the FAME studies, 416 had DME
for less than 3 years and 536 had DME for 3 years or more. The
duration of DME was indeterminate for 4 patients. At month 36,
78.8% of the chronic DME patients and 72.5% of the nonchronic
DME patients remained in the study and were receiving treatment.
The main reasons for discontinuation in both subgroups were
similar to reasons reported previously for the overall population
and were distributed evenly across the treatment groups. Duration
of exposure to treatment was similar in both subgroups (mean 
standard deviation, 990234 days and 941282 days with chronic
DME and nonchronic DME, respectively). Demographic and
baseline characteristics are shown in Table 1. Patients in the 2
subgroups were balanced with respect to age, gender, and race.
The mean duration of DME was 1.7 years and 5.2 years in thesubgroups with nonchronic and chronic DME, respectively. The
proportion of phakic patients was higher in the nonchronic DME
subgroup (73.8%) than in the chronic DME subgroup (56.1%).
Baseline ocular parameters such as mean BCVA, mean CPT,
mean area of ﬂuorescein leakage, and mean classiﬁcation on the
ETDRS multistep scale of diabetic retinopathy generally were
similar across DME duration subgroups and treatment groups.
The area of cysts was somewhat larger among patients with
chronic DME; this same trend was observed based on the
presence of laser photocoagulation scars from a special
assessment by the reading center of baseline ﬂuorescein
angiograms. Patients with chronic DME had received slightly
more steroid injections before study entry, but consistent with
the timing of the study (2005 study start), only a small but
similar percentage of patients at baseline had received intravitreal
anti-VEGF injections previously.
Effect of Fluocinolone Acetonide Implants on Visual
Acuity According to Duration of Diabetic Macular
Edema
The beneﬁt-to-risk assessment for the FAc 0.2-mg/day and FAc
0.5-mg/day doses was reported previously.15 Beneﬁt to risk was1895
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Figure 2. Graphs showing mean change from baseline in best-corrected visual acuity (BCVA) score through month 36 in patients with chronic (3 years)
or nonchronic (<3 years) diabetic macular edema (DME) at baseline. Patients were treated with ﬂuocinolone acetonide (FAc) 0.2 mg/day or sham injection
(integrated Fluocinolone Acetonide for Diabetic Macular Edema studies). The full analysis population included all randomized patients. The method of last
observation carried forward was used for imputing values for missing data. In patients with chronic DME, the mean change from baseline was þ7.6 letters
with FAc 0.2 mg/day versus þ1.8 letters with sham control treatment (P ¼ 0.004). In patients with nonchronic DME, the change in BCVA from baseline
was similar in FAc 0.2-mg/day and sham control-treated groups (þ2.4 vs. þ2.3 letters; P ¼ 0.287).
Ophthalmology Volume 121, Number 10, October 2014optimized in the FAc 0.2-mg/day group, and this is the dosage form
approved in the European countries mentioned above.15 This report
primarily focuses on comparisons between FAc 0.2-mg/day and sham
control groups using the prespeciﬁed algorithm for deﬁnition of
duration of DME, as well as an additional more precise algorithm.
As reported previously, in patients with chronic DME, a
signiﬁcantly higher proportion of FAc-treated patients in both
studies showed an improvement of 15 letters or more from baseline
at month 36 compared with sham-treated patients (FAME A: FAc
0.2 mg/day, 31.8% vs. sham, 13.6%; FAME B: FAc 0.2 mg/day,
36.4% vs. sham, 13.2%; Fig 1).15 The difference in percentage of
patients achieving a 15-letter increase or more between FAc 0.2
mg/day and sham control in FAME A was 18.3% (95% CI,
5.9e30.6; P ¼ 0.010) and in FAME B was 23.2% (95% CI,
10.0e36.3; P ¼ 0.004). In patients with nonchronic DME, a highTable 2. Anatomic Effects of Fluocinolone Acetonide Inserts and Sham
Diabetic Macu
Nonchronic Diabetic Macular
Sham Control
Fluoc
Change in area of ﬂuorescein leakage n ¼ 70
Mean (SD), disc areas 0.39 (4.323) 
Between-group difference* (P valuey) 1.31 (P ¼ 0.0
Change in area of cystoid changes n ¼ 70
Mean (SD), disc areas 0.13 (1.513) 
Between-group difference* (P valuey) 0.98 (P ¼ 0.0
2-step improvement in ETDRS diabetic
retinopathy scale
n ¼ 70
Patients (%) 10.0
Between-group difference* (P valuez) 0.1 (P ¼ 0.970
Change in macular volume n ¼ 58
Mean (SD), mm 0.95 (1.79)
Between-group difference* (P valuey) 0.74 (P ¼ 0.0
ETDRS ¼ Early Treatment of Diabetic Retinopathy Study; SD ¼ standard dev
*FAc 0.2 mg/day minus sham control.
yBetween-treatment difference and P value based on an analysis of variance m
zP value based on a Cochran-Mantel-Haenszel chi-square test stratiﬁed by base
1896percentage of patients gained 15 letters or more, but the
improvement at month 36 was comparable in FAc- and sham-
treated patients, again replicated in both trials (FAME A: FAc
0.2 mg/day, 24.1% vs. sham, 28.6%; FAME B: FAc 0.2 mg/day,
20.7% vs. sham, 27.0%). Differences between FAc 0.2 mg/day and
sham control in FAME A and FAME B were 4.5% (95%
CI, 22.2 to 13.2; P ¼ 0.441) and 6.3% (95% CI, 23.0 to 10.3;
P ¼ 0.424), respectively. Administration of FAc thus provided an
additional beneﬁt only to patients with chronic DME. In the inte-
grated dataset, the beneﬁt in the chronic DME subgroup was
observed as early as week 3 after treatment, and maximum efﬁcacy
was observed at month 30 (treatment difference in 15-letter in-
crease or more, 27.1%; P<0.001).15 At each time point, the
percentage of patients in the chronic DME group achieving this
outcome was greater with FAc treatment than with sham control.Treatments at Month 36 in Patients with Chronic or Nonchronic
lar Edema
Edema (<3 Years) Chronic Diabetic Macular Edema (‡3 Years)
inolone Acetonide
0.2 mg/day Sham Control
Fluocinolone Acetonide
0.2 mg/day
n ¼ 162 n ¼ 107 n ¼ 202
1.78 (4.167) 0.82 (4.467) 1.96 (4.157)
72) 1.28 (P ¼ 0.021)
n ¼ 162 n ¼ 107 n ¼ 202
0.77 (1.876) 0.82 (2.188) 1.02 (2.030)
03) 0.22 (P ¼ 0.413)
n ¼ 158 n ¼ 109 n ¼ 198
10.1 8.3 16.7
) 8.4 (P ¼ 0.042)
n ¼ 133 n ¼ 90 n ¼ 165
1.51 (2.01) 1.12 (1.84) 1.58 (1.77)
60) 0.79 (P ¼ 0.005)
iation.
odel with treatment and baseline visual acuity as ﬁxed effects.
line visual acuity strata.
Table 3. Study Treatments, Laser Treatments, and Off-Protocol Treatments through Month 36 in Patients with Chronic and Nonchronic
Diabetic Macular Edema
Nonchronic Diabetic Macular Edema (<3 Years) Chronic Diabetic Macular Edema (‡3 Years)
Sham Control
(n ¼ 72)
Fluocinolone Acetonide
0.2 mg/day (n ¼ 166)
Sham Control
(n ¼ 112)
Fluocinolone Acetonide
0.2 mg/day (n ¼ 209)
Study treatments (sham injection or ﬂuocinolone acetonide implant), %
1 treatment 80.6 72.7 66.1 76.1
2 treatments 16.7 24.8 27.7 18.7
3 treatments 2.8 2.4 6.3 5.3
Rescue laser treatments (at masked physician’s discretion after week 6)
Patients, n (%) 45 (62.5) 71 (42.8) 69 (61.6) 85 (40.7)
P value 0.136 0.003
Off-protocol treatments
Any, n (%) 22 (30.6) 29 (17.5) 39 (34.8) 28 (13.4)
P value 0.023 <0.001
IVTA, n (%) 11 (15.3) 12 (7.2) 27 (24.1) 17 (8.1)
P value 0.057 <0.001
Anti-VEGF, n (%) 10 (13.9) 5 (3.0) 17 (15.2) 7 (3.3)
P value 0.002 <0.001
IVTA ¼ intravitreal triamcinolone acetonide; VEGF ¼ vascular endothelial growth factor.
Cunha-Vaz et al  Fluocinolone Acetonide Implant for Chronic DMEOf note, in comparing the sham control subgroups (chronic vs.
nonchronic), the response rate in terms of 15-letter or more
improvement of BCVA at 36 months was 2-fold higher among
patients with nonchronic DME compared with patients with
chronic DME, despite similar background treatments in both sub-
groups (27.8% vs. 13.4%; P ¼ 0.012).
The mean change from baseline BCVA letter score at month 36
was greater with FAc treatment than with sham control treatment in
patients with chronic DME (FAc 0.2 mg/day, þ7.6 letters;
sham, þ1.8 letters; Fig 2). The between-treatment difference in
mean change from baseline at month 36 based on analysis of
variance was 6.1 letters (95% CI, 2.0e10.2; P ¼ 0.004). The
improvement in BCVA with FAc implants in the chronic DME
subgroup occurred within 1 week of initiating treatment (P ¼
0.020). By contrast, in patients with nonchronic DME, improve-
ments in BCVA at month 36 were similar across treatment groups
(FAc 0.2 mg/day, 2.4 letters; sham, 2.3 letters; difference from
sham, 3.1; 95% CI, 2.6 to 8.8; P ¼ 0.287).Figure 3. Bar graph showing study, laser, and off-protocol treatments
administered per patient per year over 36 months in patients with chronic
(3 years) or nonchronic (<3 years) diabetic macular edema (DME) at
baseline. Control patients in the chronic DME population seemed to be
somewhat more heavily treated in the second and third years. The intensity
of treatment did not correlate with functional improvement. FAc ¼ ﬂuo-
cinolone acetonide.Anatomic Changes
A rapid and signiﬁcant reduction in mean CPT was observed after
treatment with FAc implants in patients with duration of DME of 3
years or more or of less than 3 years.15 In patients with chronic
DME, the mean change in CPT at month 36 was 160.0 mm in
the sham control group and 186.8 mm in the FAc 0.2-mg/day
group (difference from sham, 38.2 mm; 95% CI, 13.3 to 89.8;
P ¼ 0.146). In patients with nonchronic DME, mean change in
CPT at month 36 was 115.6 mm with sham control treatment
and 173.1 mm with FAc 0.2 mg/day (difference from sham,
74.1 mm; 95% CI, 4.7e143.6; P ¼ 0.036). Although reduction
in CPT was more rapid with FAc 0.2 mg/day than with sham
control treatment in both DME subgroups, the difference in year
3 anatomic status between treatment groups was not clinically
relevant. In the chronic DME subgroup, the striking difference in
visual improvement with FAc versus sham control treatment was
not accompanied by a similar difference in reduction of retinal
edema in year 3 of the study.15
Similarly, measures of anatomic change at month 36 versus
baseline based on ﬂuorescein leakage, area of cysts, or macular
volume were not consistent with visual acuity changes (Table 2).For example in the nonchronic DME population, there was
greater reduction of ﬂuorescein leakage with FAc 0.2 mg/day
(1.78 disc areas) compared with sham control treatment (0.39
disc areas), yet the 15-letter or more response did not differ be-
tween these groups. Further, with sham control treatment, despite a
smaller reduction of ﬂuorescein leakage in the nonchronic than in
the chronic DME population, functional outcomes were signiﬁ-
cantly better in the nonchronic than in the chronic DME popula-
tion. Similar relationships were evident for the area of cysts. For
macular volume, the change over time was similar to that observed
for CPT, and as with CPT, the year 3 measurement was similar
between the sham control and FAc 0.2-mg/day groups for both
chronic and nonchronic DME populations.
Furthermore, changes in retinopathy at year 3, graded by a
qualiﬁed reading center using the ETDRS step changes, did not
reﬂect the functional treatment effects noted in the DME subgroups
based on a worsening of 3 or more steps because of the small1897
Figure 4. Graph showing the proportion of patients with a 15-letter or
more increase from baseline best-corrected visual acuity at month 24
(primary outcome) by duration of diabetic macular edema (DME; 3 years
or <3 years at baseline). The graph shows a trend of increased treatment
effect for ﬂuocinolone acetonide (FAc) 0.2 mg/day versus sham control
treatment with increasing duration of DME based on the prespeciﬁed
duration algorithm in the integrated Fluocinolone Acetonide for Diabetic
Macular Edema studies.
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higher proportion of patients with chronic DME who received FAc
0.2 mg/day experienced a 2-step or more improvement in retinop-
athy versus patients who received sham control treatment, and the
opposite was seen in the nonchronic patients (Table 2). The
differential treatment effect seen with this measure is consistent
with the differential treatment effect seen based on visual acuity.
Additional Treatments
As shown in Table 3, the proportion of patients receiving
additional study treatments, rescue laser treatments, or off-
protocol therapies within each treatment group was similar
for chronic versus nonchronic DME. Differences in treatments
received thus did not explain the signiﬁcant differences in
treatment effect between these subpopulations. Notably, in
both DME subgroups, the sham control group received
signiﬁcantly more laser and off-protocol treatments compared
with the FAc 0.2-mg/day group, likely reﬂecting the efﬁcacy
of the steroid-releasing implant in controlling the disease.
Figure 3 provides a breakdown of treatments administered per
patient per year in each DME subgroup over the 3-year study
duration. Sham-treated patients with chronic DME seemed to
be somewhat more heavily treated than those with nonchronic
DME in the second and third years, especially with off-
protocol therapies, presumably because of the severity of
their disease.
An examination of the 15-letter or more response at month 36
in sham control-treated patients showed that the chronic DME
subgroup achieved a 13.4% response, whereas the nonchronic1898DME subgroup achieved a 27.8% response (P ¼ 0.012). This
difference signiﬁcantly favored patients with nonchronic DME
despite the fact that sham control-treated patients with chronic
DME received more off-protocol treatments in the latter years. This
observation suggests that intermittent treatment with targeted
therapies is not sufﬁcient to control disease in the chronic DME
subgroup, providing insight on the transition to a chronic disease
state.
Robustness of the Treatment Effect
Treatment Effect According to More Precise Determination of
Duration of Diabetic Macular Edema. To ensure that the signiﬁ-
cant, reproducible difference in treatment effect observed between
the chronic and nonchronic subgroups was not the result of an
anomaly based on a single time point of 3-year duration of diag-
nosis of DME, we performed an exploratory analysis of the
treatment effect based on 15-letter or more increase from baseline
BCVA as a function of the precise duration of DME at randomi-
zation, rather than a median cutoff. Figure 4 shows the response at
the primary end point of 24 months and demonstrates a clear trend
toward an increasing treatment effect with increased duration of
DME. This pattern of increasing response with FAc treatment
compared with sham control treatment also was observed when
30- and 36-month efﬁcacy were analyzed.
Treatment Effect with Alternative Calculation of Median
Duration of Diabetic Macular Edema. To probe further the
robustness of the results, an alternative algorithm was used to
determine duration of diagnosis of disease. The algorithm resulting
in a median duration of 3 years was based on year of randomization
minus year of diagnosis plus 1. The alternative calculation was
based on the speciﬁc day, month, and year of diagnosis of DME;
for 75% of the population, the day, month, and year were known
for these dates. For 10% of the population, only the month and year
were available for date of diagnosis, so the 15th of the month was
imputed for the day. For another 15% of the population, only the
year was available for the date of diagnosis, so a date of July 1 was
imputed. This resulted in a new median duration of 1.73 years, with
duration of less than 1.73 years in 475 patients and of 1.73 years or
more in 477 patients.
For both the FAME A and B trials, the relative treatment effect
between the chronic and nonchronic populationswas almost identical,
regardless of the algorithm used to calculate the median duration of
DME (Fig 5, available at www.aaojournal.org). A signiﬁcant number
of patients (92.6%; 43.1þ49.5) retained the same chronic or
nonchronic categorization with the new algorithm (Table 4,
available at www.aaojournal.org). The k value for concordance was
0.8508, representing very strong agreement between both
algorithms (P<0.0001). The percentages of patients at month 36
with an improvement in BCVA of 15 letters or more in FAME A
for DME of less than 1.73 years’ duration were sham, 30% versus
FAc 0.2 mg/day, 27.1% (P ¼ 0.612); and for DME of 1.73 years’
duration or more, sham, 11.1% versus FAc 0.2 mg/day, 30.1% (P ¼
0.010). In FAME B, these percentages for DME of less than 1.73
years’ duration were sham, 26.8% versus FAc 0.2 mg/day, 22.9%
(P ¼ 0.563); and for DME of 1.73 years’ duration or more, sham,
12.2% versus FAc 0.2 mg/day, 35.6% (P ¼ 0.004). For the
integrated dataset, changes in mean CPT were similar for chronic
and nonchronic DME, both showing a rapid reduction in thickness
in the FAc 0.2-mg/day groups and a gradual reduction in the sham
control groups (Fig 6). The proportion of patients with 15-letter or
more improvement at 36 months (Fig 6) in those with DME of 1.73
years’ duration or more was 11.7% for sham control and 32.8% for
FAc 0.2 mg/day (treatment difference of 21.1%; 95% CI,
11.9e30.3; P<0.001). In patients with DME of less than 1.73
years’ duration, values at month 36 were 28.4% for sham control
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Figure 6. Graphs showing the mean center point thickness (CPT) and 15-letter or more response through month 36 in patients with diabetic macular
edema (DME) of 1.73 years’ duration or more or less than 1.73 years’ duration at baseline. Patients were treated with ﬂuocinolone acetonide (FAc) 0.2 mg/
day or sham injection (integrated Fluocinolone Acetonide for Diabetic Macular Edema studies). The full analysis population included all randomized
patients. The method of last observation carried forward was used for imputing values for missing data. The CPT changes did not reﬂect the signiﬁcant
improvement in visual acuity obtained with FAc 0.2 mg/day at month 36 compared with sham control treatment. In patients with chronic DME, (A) the 36-
month mean reduction in CPT was 153.7 mm in the sham control group and 184.6 mm in the FAc 0.2-mg/day group (treatment difference, 43.3 mm; 95%
conﬁdence interval [CI], 10.6 to 97.3; P ¼ 0.115), and (B) the proportion of patients with 15-letter or more improvement was 11.7% in the sham control
group and 32.8% in the FAc 0.2-mg/day group (treatment difference, 21.1%; 95% CI, 11.9e30.3; P<0.001). In patients with nonchronic DME, (C) the 36-
month mean reduction in CPT was 128.6 mm with sham control treatment and 177.2 mm with FAc 0.2 mg/day (treatment difference, 62.9 mm; 95%
CI, 1.4 to 127.2; P ¼ 0.055), and (D) the proportion of patients with 15-letter or more improvement was 28.4% for sham control treatment and 25.0% for
FAc 0.2-mg/day treatment (treatment difference, 3.4%; 95% CI, 15.0 to 8.2; P ¼ 0.447).
Cunha-Vaz et al  Fluocinolone Acetonide Implant for Chronic DMEand 25.0% for FAc 0.2 mg/day (treatment difference, 3.4%; 95%
CI, 15.0 to 8.2; P ¼ 0.447). The mean change in BCVA (Fig 7,
available at www.aaojournal.org) also was similar between the
original and new algorithms. Overall, the results showing greater
efﬁcacy of FAc in patients with duration of DME longer than the
median thus were consistent regardless of the method used to
calculate the median.
Adverse Events
As with the overall population, elevation of IOP and cataract were
the primary adverse events that were considered drug related
(Table 5). Depending on the IOP parameter evaluated, trends in
favor of both shorter and longer duration of disease were
observed, but there was no consistent signal that would inﬂuence
patient management of this class side effect. Intraocular pressure-
lowering medications were required by 12.5% to 15.2% of pa-
tients in the sham control group and 35.9% to 41.8% of patients in
the FAc 0.2-mg/day group. Use of laser and off-protocol therapies
may have inﬂuenced the need for IOP-lowering therapies,particularly in the sham control group. The proportion of patients
experiencing IOP- or cataract-related adverse events was similar
regardless of the algorithm used (Table 6, available at
www.aaojournal.org).
Most phakic patients receiving FAc 0.2 mg/day demonstrated a
cataract, and as in the overall population, most cataracts were re-
ported and extracted by month 24, so that visual outcomes in year 3
were free of confounding by cataract. In the chronic DME sub-
group, 36-month visual outcomes with FAc 0.2 mg/day treatment
were numerically higher in patients who became pseudophakic
during the study (improvement in BCVA score of þ11 letters) than
in those who were pseudophakic at baseline (improvement in
BCVA score of þ7 letters). This difference was not observed in the
nonchronic population (month 36 change from baseline in BCVA
letter score of þ3.3 letters for patients pseudophakic at baseline
versus þ4.3 letters for phakic patients who became pseudophakic).
Thus, long-term visual outcomes in patients with chronic DME
were not compromised by cataract surgery after treatment with the
FAc implant. Considering only those patients who were pseudo-
phakic at baseline, the treatment differences in 15-letter or more1899
Table 5. Incidence of Relevant Ocular Adverse Events in Patients with Chronic and Nonchronic Diabetic Macular Edema
Nonchronic Diabetic Macular Edema (<3 Years) Chronic Diabetic Macular Edema (‡3 Years)
Sham Control Fluocinolone Acetonide 0.2 mg/day Sham Control Fluocinolone Acetonide 0.2 mg/day
IOP-related events (n ¼ 72) (n ¼ 165) (n ¼ 112) (n ¼ 209)
Elevation considered an AE* 6 (8.3) 67 (40.6) 16 (14.3) 72 (34.4)
Any IOP-lowering medicationy 9 (12.5) 69 (41.8) 17 (15.2) 75 (35.9)
IOP-related surgeryz 1 (1.4) 7 (4.2) 0 (0.0) 11 (5.3)
Cataract-related events in phakic patients (n ¼ 54) (n ¼ 121) (n ¼ 66) (n ¼ 114)
Any cataract 26 (48.1) 94 (77.7) 34 (51.5) 98 (86.0)
Cataract operation 8 (14.8) 91 (75.2) 24 (36.4) 97 (85.1)
AE ¼ adverse event; IOP ¼ intraocular pressure.
*Includes AE reports of ocular hypertension and IOP increased.
yFor a minimum of 7 days.
zIncludes trabeculectomy, glaucoma surgery, or vitrectomy for elevated IOP.
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groups were similar to those of the full population. Among patients
with chronic DME who were pseudophakic at baseline, 31.6% of
patients in the FAc 0.2-mg/day group and 17.4% of those in the
sham control group experienced 15-letter or more improvement at
month 36 (P ¼ 0.043). Among pseudophakic patients with non-
chronic DME, 25.0% of patients in the FAc 0.2-mg/day group and
16.7% of those in the sham control group experienced 15-letter or
more improvement at month 36 (P ¼ 0.672). Results were similar
for the new algorithm (Fig 8, available at www.aaojournal.org).
Therefore, the differential treatment effects noted between
chronic and nonchronic patients is not an artifact of cataract
surgery.Discussion
In the FAME studies, FAc implants provided a substantial
visual beneﬁt for up to 3 years in patients with vision
impairment (ETDRS vision between 19 and 68 letters) and
center-involved DME who had undergone at least 1 prior
macular laser treatment.14,15 A preplanned subgroup
analysis that examined visual outcomes as a function of
duration of DME at randomization (above or below the
median duration) revealed that the treatment effect resided
primarily in patients with chronic DME. Regardless of the
algorithm used to calculate duration of DME, the treatment
effect for chronic DME was highly signiﬁcant and was
reproduced in both phase 3 trials. For the nonchronic DME
group, no signiﬁcant treatment effect was seen in either
FAME A or B. However, patients with nonchronic DME
treated with FAc 0.2-mg/day implants did receive signiﬁ-
cantly fewer laser and off-protocol therapies compared with
patients with nonchronic DME in the sham control group.
Baseline ocular characteristics, including BCVA and
anatomic features, did not differ signiﬁcantly between the
subgroups with nonchronic DME or chronic DME, other
than a lower proportion of phakic patients in the chronic
DME subgroup. An analysis of cataract and vision outcomes
(Yang Y, et al, manuscript in preparation) did not reveal any
impact of baseline lens status on the differences in vision
noted in patients with chronic or nonchronic DME. The
differential vision beneﬁt with FAc implants between the
chronic and nonchronic DME groups also was not linked to1900changes in anatomic outcomes. Compared with sham con-
trol treatment, long-term improvements in CPT and macular
volume with FAc implants were similar in both DME sub-
groups. When compared with sham control treatment, FAc
implants reduced the area of cysts to a greater extent in
patients with nonchronic DME, indicating that the vision
beneﬁt in patients with chronic DME was not associated
with improvements in cystoid pathologic features. A greater
reduction in area of ﬂuorescein leakage was reported for
FAc-treated patients compared with sham control patients in
both chronic and nonchronic populations; a slightly larger
treatment effect was observed in nonchronic patients, which
was inconsistent with the treatment effect on vision. The
comparison of the proportion of patients with 2-step or more
improvement in retinopathy did correlate with the functional
treatment effects. These data suggest that with the methods
used, anatomic and functional responses to FAc are not
related directly to each other in patients with chronic DME.
A differential re-treatment rate did not account for the
improved efﬁcacy of FAc in patients with chronic DME.
Study treatment could be repeated after month 12 in patients
with persistent or recurrent DME if re-treatment criteria
were met. Re-treatment was allowed because the duration of
release of FAc was not known when the studies were
initiated. It was determined subsequently to be at least 3
years for the 0.2-mg/day dose.17 Given the sustained efﬁcacy
of FAc at 3 years and the associated release proﬁle, re-
treatment within the ﬁrst 3 years may not be needed. In
sham-treated patients, rates of re-treatment were slightly
higher for those with chronic DME than for those with
nonchronic DME, likely reﬂecting the refractoriness of
long-standing DME to current treatment strategies. How-
ever, rates of re-treatment with FAc were similar for both
DME subgroups. Sham-treated patients in both DME sub-
groups also underwent more laser treatments and received
more disallowed therapies than those who received FAc in
either subgroup. Notably, in years 2 and 3, sham control-
treated patients with chronic DME received the highest
number of off-protocol treatments per patient (vs. non-
chronic sham control or either FAc 0.2-mg/day subgroup),
again reﬂecting the true refractory nature of this group of
patients. Among patients receiving FAc treatment, there was
no difference in use of these therapies between the
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re-treatment or receipt of other therapies was similar
regardless of DME duration and did not account for the
greater efﬁcacy of FAc in patients with chronic DME.
Our data conﬁrm that the sham control populations in
both DME subgroups were receiving the available standard
of care. Although additional laser therapy was allowed after
6 weeks in the study, other therapies such as intravitreally
administered triamcinolone acetonide or anti-VEGF anti-
bodies were not allowed per the protocol (all were off-label
therapies at the time). However, many sites administered
these therapies because they are part of the standard of care
and because of the long (3-year) duration of the study. The
similar incidence of re-treatment with study drug, which was
recommended by a masked assessing investigator, in sham-
and FAc-treated patients, points to the effectiveness of
masking (i.e., if the masked investigator knew a patient was
randomized to the sham arm, they would not recommend re-
treatment with a sham injection). The ﬁnding that ancillary
therapies were administered more frequently in the sham
control group indicates that decisions to prescribe these
therapies were therapeutically driven and that the sham
control groups were receiving the available standard of care.
The fact that the chronic DME sham control group had a
poor response to these available therapies (compared with
the nonchronic DME sham control group, which did
respond to the available therapies) and that the treatment
effect of the chronic group with the addition of FAc is
signiﬁcant (34.0% for FAc 0.2 mg/day vs. 13.4% for sham
control; P ¼ 0.002) shows that the chronic population was
insufﬁciently responsive to available therapies, which were
standard of care at the time of the trial.
Safety ﬁndings in patients with chronic DME or non-
chronic DME essentially were similar. Adverse effects of
greatest concern with corticosteroid therapy are cataracts and
elevated IOP. A dose response was seen for IOP increases in
favor of the low dose. Interestingly, signals of IOP elevation
including elevated IOP reported as an adverse event and use
of topical IOP-lowering therapy were numerically lower in
the chronic DME population; however, this trend was not
maintained regarding surgery for elevated IOP. The latter,
however, involved small numbers. Almost all phakic pa-
tients in both subgroups who received FAc underwent
cataract surgery. Cataract surgery was completed on almost
all patients by the end of year 2. In comparing pseudophakic
patients with phakic patients treated with FAc 0.2 mg/day
who became pseudophakic, no signiﬁcant difference in long-
term vision outcome was seen in patients with nonchronic
DME. However, in chronic DME patients, a beneﬁt in favor
of the FAc implants was observed. This suggests a protec-
tive effect for vision recovery of the FAc implants in patients
with chronic DME undergoing cataract surgery.
Two distinct features of the FAME studies allowed for
the signiﬁcant treatment effect of FAc implants in chronic
DME to be detected. First, the requirement of at least 1 prior
macular laser treatment in the FAME studies was unique
among phase 3 trials of therapies for DME, and it inad-
vertently enriched the study population for patients with
chronic DME. Second, the FAc implants deliver continuous,
multiyear, submicrogram daily doses of corticosteroid.17 Bycontrast, intravitreal triamcinolone acetonide requires
intermittent dosing because the short duration of release
does not allow a constant drug level to be maintained;
over a 2-year period, a mean of 3 treatments was
administered.18
Not only did the FAME studies assess the therapeutic
potential of FAc implants, but they also provided information
on the natural history of DME. Alterations in the microenvi-
ronment of the retina may be expected in concert with the
evolving chronic vascular dysfunction associated with dia-
betes. The pathogenesis of DME encompasses inﬂammatory
and neurodegenerative components. Inﬂammatory changes
detected in retinas of diabetic animals or patients include
leukostasis, vascular leakage, ischemia, and increased levels
of proinﬂammatory cytokines such as tumor necrosis factor-a,
interleukin-6, interleukin-8, VEGF, and chemoattractant pro-
teins.19 Diabetic retinopathy also is marked by hypertrophy
and activation of retinal microglia, which contribute to
neuronal damage by release of neurotoxic substances.20
Corticosteroids inhibit inﬂammatory processes implicated in
DME, including production of proinﬂammatory mediators,
increased levels of VEGF, and loss of endothelial tight
junction proteins,21,22 leading to suppression of retinal
edema and neovascularization,23,24 and also may function as
neuroprotectants in the retina.25e27 Early stages of DME may
be characterized by acute inﬂammation and vascular
dysfunction, whereas at later stages, chronic inﬂammation and
neuronal damage may be more prominent. These large
multinational trials provided an adequate sample size to
compare the effect of continuous, low-dose corticosteroid
treatment in patients with chronic versus nonchronic disease.
In this study, responses in the sham control-treated pop-
ulations are suggestive of the evolving pathophysiology of
DME at 2 different stages. Nonchronic DME responded to
intermittent laser and pulse intravitreal therapies, and the
addition of continuous, low-dose corticosteroid therapy did
not add signiﬁcant visual acuity beneﬁt. By contrast, chronic
DME did not respond adequately to laser and pulse therapies,
but did beneﬁt signiﬁcantly from continuous, low-dose
corticosteroid therapy. Although the mechanism is unclear,
we hypothesize that increased levels of inﬂammatory cyto-
kines, anatomic cellular changes related to neuronal cell loss
and glial proliferation, as well as physiological alterations that
evolve over time yield a scenario whereby the response
characteristics of the retina are altered for various treatments.
A similar shift in the disease also was observed in 2
phase 3 clinical trials of ranibizumab, dosed monthly. In
both trials, the sham control population, crossed over to
monthly injections of the anti-VEGF antibody after 2 years,
did not show a visual response as great as those patients who
received treatment during the ﬁrst 2 years.11 Thus, 4 phase 3
clinical trials suggest that an underlying pathophysiologic
alteration occurs in some patients with DME after
approximately 2 years.
The primary algorithm used to calculate duration of
DME at baseline resulted in a median duration of 3 years,
whereas an alternative algorithm resulted in a median
duration of 1.73 years. The alternative algorithm, which
used the day, month, and year of diagnosis when available,
resulted in a more precise determination of duration of1901
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determination of duration of DME. No guidance was pro-
vided for determining dates of diagnosis; rather, duration at
randomization was based on information recorded at
screening by investigators, who relied on their best clinical
judgment and knowledge of each patient’s history. Patient
recall and incomplete chart records could impact the date
recorded at the start of the study, as could the duration of
undiagnosed DME. Interestingly, at more than 100 clinical
sites, the determination used by investigators was consistent
enough for the dramatically different treatment effect in
chronic versus nonchronic DME to be observed reproduc-
ibly in both FAME phase 3 clinical trials. This shift from
nonchronic to chronic DME will be unique to each patient,
and basing treatment decisions on a preset duration of dis-
ease, such as 2 or 3 years, would not be logical. However,
we hypothesize that lack of response to laser or anti-VEGF
antibody therapy may be a diagnostic sign of a shift to a
more chronic phenotype, and treatment decisions should be
based on this instead. The low-dose FAc implants delivering
0.2 mg/day provide visual acuity beneﬁt while minimizing
the adverse event of greatest concern, namely, elevation of
IOP requiring surgery. The analyses presented in this article
are the ﬁrst to relate treatment effect to duration of diagnosis
of DME. The primary adverse events of cataract and
elevation of IOP are known, class-related adverse events
that can be detected readily and effectively treated. In pa-
tients with a microenvironmental shift to chronic DME, a
therapy that targets multiple mediators could provide beneﬁt
to patients who do not respond to targeted therapy.
Currently, corticosteroids are the only class of drug with
such a multifactorial pharmacologic proﬁle. The FAc 0.2-
mg/day implants are the only dosage form releasing
continuous, daily, submicrogram corticosteroid over a
multiyear period that also provide a signiﬁcant beneﬁt to
patients whose DME has become chronic.
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Figure 5. Proportion of patients with 15-letter improvement from baseline in best-corrected visual acuity by study and duration of diabetic macular edema
using the new algorithm ( or <1.73 years). Visual outcomes through month 36 in patients with chronic or nonchronic diabetic macular edema (DME) at
baseline treated with ﬂuocinolone acetonide (FAc) 0.2 mg/day or sham injection in the ﬂuocinolone acetonide for diabetic macular edema (FAME) A and
FAME B studies. The full analysis population included all randomized patients. The method of last observation carried-forward was used for imputing values
for missing data. In patients with chronic DME, a signiﬁcantly higher proportion of patients treated with FAc gained 15 letters from baseline compared
with the sham control group in both FAME studies, (A) FAME A: FAc 0.2 mg/day, 30.1% vs sham control, 11.1% P ¼ 0.010; (B) FAME B: FAc 0.2 mg/day,
35.6% vs sham control, 12.2%, P ¼ 0.004. In patients with nonchronic DME, the percentage of patients who gained 15 letters from baseline was similar
between FAc-treated and sham control groups in both studies, (C) FAME A: FAc 0.2 mg/day, 27.1% vs sham control, 30.0%; P ¼ 0.612; (D) FAME B: FAc
0.2 mg/day, 22.9% vs sham control, 26.8%; P ¼ 0.563.
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Figure 7. Mean change from baseline in best-corrected visual acuity (BCVA) score through month 36 in patients by duration of DME using the new
algorithm ( or <1.73 years). Patients were treated with ﬂuocinolone acetonide (FAc) 0.2 mg/day or sham injection (integrated ﬂuocinolone acetonide for
diabetic macular edema [FAME] studies). The full analysis population included all randomized patients. The method of last observation carried-forward was
used for imputing values for missing data. In patients with chronic DME, the mean change from baseline was þ7.3 letters with FAc 0.2 mg/day versus þ0.7
letters with sham control treatment (P ¼ 0.001). In patients with nonchronic DME, the change in BCVA from baseline was similar in FAc 0.2 mg/day and
sham control-treated groups (þ3.4 vs þ3.7 letters; P ¼ 0.555).
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Figure 8. Proportion of patients who were pseudophakic at baseline with 15-letter improvement from baseline in best-corrected visual acuity by study and
duration of diabetic macular edema using the new algorithm ( or <1.73 years). (A) Pseudophakic, DME  1.73 years: FAc 0.2 mg/day, 33.7% vs sham
control, 13.6%; P ¼ 0.006; (B) Pseudophakic, DME <1.73 years: FAc 0.2 mg/day, 23.2% vs sham control, 25.0%.
Table 4. Concordance Between Original and Secondary Algo-
rithms Calculating the Duration of Diabetic Macular Edema
Secondary Algorithm
< 1.73 Years  1.73 Years
Original algorithm < 3 Years, n (%) 410 (43.1) 6 (0.6)
 3 Years, n (%) 65 (6.8) 471 (49.5)
Kappa*
0.8508
P value
< 0.0001
*Measures agreement ranging from 1 (complete discordance) to þ1
(complete concordance).
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Table 6. Incidence of Relevant Ocular AEs in Patients with DME  or < 1.73 Years
DME < 1.73 Years DME ‡ 1.73 Years
Sham Control (n ¼ 81) FAc 0.2 mg/day (n ¼ 191) Sham Control (n ¼ 103) FAc 0.2 mg/day (n ¼ 183)
IOP-related events
Elevation considered an AE* 7 (8.6) 75 (39.3) 15 (14.6) 64 (35.0)
Any IOP-lowering medicationy 10 (12.3) 78 (40.8) 16 (15.5) 66 (36.1)
IOP-related surgeryz 1 (1.2) 10 (5.2) 0 (0.0) 8 (4.4)
Sham Control (n ¼ 61) FAc 0.2 mg/day (n ¼ 135) Sham Control (n ¼ 59) FAc 0.2 mg/day (n ¼ 100)
Cataract-related events in phakic patients
Any cataract 28 (45.9) 106 (78.5) 32 (54.2) 86 (86.0)
Cataract operation 10 (16.4) 105 (77.8) 22 (37.3) 83 (83.0)
DME, diabetic macular edema; FAc, ﬂuocinolone acetonide; IOP, intraocular pressure.
*Includes adverse event reports of ocular hypertension and intraocular pressure increased.
yFor a minimum of 7 days.
zIncludes trabeculectomy, glaucoma surgery, or vitrectomy for elevated IOP.
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